Abstract
Since additive manufacturing of pharmaceuticals has been introduced as viable method to produce individualized drug delivery systems with complex geometries and release profiles, semi-solid micro-extrusion has shown to be uniquely beneficial. Easy incorporation of actives, room-temperature processability and avoidance of cross-contamination by using disposables are some of the advantages that led many researchers to focus their work on this technology in the last few years. First acceptability and in-vivo studies have brought it closer towards implementation in decentralized settings. This review covers recently established process models in light of viscosity and printability discussions to help develop high quality printed medicines. Quality defining formulation and process parameters to characterize the various developed dosage forms are presented before critically discussing the role of semi-solid micro-extrusion in the future of personalized drug delivery systems. Remaining challenges regarding regulatory guidance and quality assurance that pose the last hurdle for large scale and commercial manufacturing are addressed.
Original language | English |
---|---|
Pages (from-to) | 104-126 |
Number of pages | 23 |
Journal | Advanced Drug Delivery Reviews |
Volume | 172 |
DOIs | |
Publication status | Published - May 2021 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2021 Elsevier B.V.
Keywords
- 3D-printing
- Additive manufacturing
- Critical quality attributes
- Drug delivery systems
- Personalized therapy
- Process analytical technology (PAT)
- Process and formulation requirements
- Process models
- Semi-solid micro-extrusion